Related Experiment Videos

Cholecalciferol metabolites in polycythemic newborns

Israel Journal of Medical Sciences
|February 1, 1985
PubMed

Insights

Polycythemic newborns have lower levels of vitamin D metabolites, specifically 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D. This may be due to reduced kidney blood flow affecting vitamin D conversion.

Area of Science:

  • Neonatal Medicine
  • Endocrinology
  • Pediatric Nephrology

Background:

  • Vitamin D (cholecalciferol) is crucial for infant health.
  • Its active metabolites, 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D, are primarily produced in the kidneys.
  • Neonatal polycythemia is a condition characterized by high red blood cell counts.

Purpose of the Study:

  • To investigate serum concentrations of vitamin D metabolites in newborns with polycythemia.
  • To explore the potential impact of polycythemia on vitamin D metabolism.

Main Methods:

  • Serum samples were collected from healthy and polycythemic newborns.
  • Concentrations of cholecalciferol metabolites, including 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D, were measured.
  • Measurements were taken at specific ages (median 15.5h for healthy, 10.5h for polycythemic).

Main Results:

  • Polycythemic newborns exhibited significantly lower serum concentrations of 1,25-dihydroxyvitamin D (P < 0.003).
  • Serum levels of 24,25-dihydroxyvitamin D were also significantly lower in the polycythemic group (P < 0.001).

Conclusions:

  • Neonatal polycythemia is associated with reduced levels of key vitamin D metabolites.
  • Impaired renal blood flow secondary to hyperviscosity in polycythemia may hinder the kidney's conversion of vitamin D metabolites.

Related Concept Videos